Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

Abzena's Antitope subsidiary to share in Eurostars grant

A consortium of which Abzena subsidiary Antitope is a part has been awarded a €1.9mln grant under the Eurostars programme.
Abzena's Antitope subsidiary to share in Eurostars grant
The consortium is developing a novel treatment for clotting disorders

Abzena (LON:ABZA) said a consortium of which its Antitope subsidiary is a part has been awarded a €1.9mln grant under the Eurostars programme.

Other members of the consortium are: Prothix BV; Aristi Biotech BV; the University Medical Center Utrecht; and GenOnway.

The consortium is developing a novel treatment for clotting disorders, targeting anti-thrombin III, a protein that inhibits blood clotting. The novel antibody has the potential to both prevent and treat bleeding in patients with disorders such as haemophilia.

Neil Butt, vice president of Business Development at Abzena, said: "Applying our Composite Human Antibody technology to this novel product will help produce a less immunogenic version, giving it a greater chance of improving the lives of patients."

Antitope provides immunogenicity assessment, protein engineering to create humanised antibodies and de-immunised therapeutic proteins, and cell line development for manufacture.

The Eurostars Programme is a European joint programme dedicated to giving a leg-up to small-to-medium sized research & development companies.

Shares in Abzena were up 1.8% at 56p in morning trade.

John-H.jpg
Why Invest In Abzena plc? Read More Here

Register here to be notified of future ABZA Company articles
View full ABZA profile

Abzena plc Timeline

Big Picture
September 13 2016

Related Articles

Test-tubes_opt_56d69b8aa24bf.jpg
March 02 2016
The company's results reveal a company in rude health - and one still on the acquisition trial.
World map made out of drugs
April 12 2016
The pharma services and drug development group has hit key milestones in the last year.
biotech_564b2dac17b4d.jpg
November 17 2015
Biotech Summit Therapeutics (LON:SUMM is edging closer to a huge 'inflection point', which could potentially transform its fortunes.

© Proactive Investors 2016

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.